Skiplinks


Breadcrumb

Projects

 

filter projects

Selected values All


Page 1

618 Results (on 31 pages)
Show results on one page
No. ^v Title ^v Status ^v Last updt ^v  
A17-26Rolapitant (prevention of nausea and vomiting in chemotherapy) - Benefit assessment according to §35a Social Code Book VCommission work started2017-07-25
A17-27Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)Commission work started2017-07-25
N14-02Systemic therapy in adults as a psychotherapeutic approachCommission completed2017-07-24
N16-02Telemonitoring using active cardiac implantable devices in ventricular tachyarrhythmia and heart failureReport plan published2017-07-11
A17-18Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book VCommission work started2017-07-11
A17-23Pembrolizumab (classical Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book VCommission work started2017-07-11
A17-24Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book VCommission work started2017-07-11
D15-01Optical coherence tomography (OCT) for neovascular age-related macular degeneration as well as diabetic retinopathy with macular oedemaCommission completed2017-07-07
A16-70Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritisReport plan published2017-07-06
A17-22Reslizumab (asthma) - Addendum to Commission A17-02Commission completed2017-07-06
H17-01Ultrasound-guided high-intensity focused ultrasound for uterine fibroids – Addendum to commission H16-02BCommission completed2017-07-05
H17-02Ultrasound-guided high-intensity focused ultrasound for malignant neoplasms of the liver and intrahepatic bile ducts – Addendum to commission H16-02DCommission completed2017-07-05
A17-11Dolutegravir (HIV infection) - Benefit assessment according to §35a Social Code Book VCommission completed2017-07-03
A17-14Baricitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book VCommission completed2017-07-03
A17-12Axitinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)Commission completed2017-07-03
A17-13Tenofovir alafenamide (chronic hepatitis B) – Benefit assessment according to §35a Social Code Book VCommission completed2017-07-03
GA17-02Examination of the usability of the scientific use files of the ZfKD in the framework of the determination of the SHI target populationCommission work started2017-06-27
N17-01Negative pressure wound therapyReport plan published2017-06-26
P17-02Concept for a national health portalCommission work started2017-06-21
A17-16Trametinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book VCommission work started2017-06-21

Page 1

618 Results (on 31 pages)
Show results on one page
to top

Glossary entries